GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alterity Therapeutics ATHE · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.43

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

—

FY2017FY2026

Net income

−$16.3m

FY2017FY2026

Free cash flow

−$31.4m

FY2017FY2026

Shareholders' equity

$30.4m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue—$3.9m$2.9m$2.8m$3.6m$3.1m$293,025$77,276$143,231$94,262
Research and development$12.3m$10.3m$13.3m$9.4m$10.5m$8.7m$7.2m$9.2m$4.8m$4.1m
Operating income−$19.8m−$10.4m−$14.0m−$10.4m−$11.0m−$10.8m−$7.4m−$9.1m−$5.5m−$4.9m
Net income−$16.3m−$8.6m−$13.6m−$9.8m−$9.1m−$10.9m−$7.2m−$8.5m−$5.9m−$5.4m
Diluted earnings per share-0.90-0.51-1.54-2.36-2.28-2.72-3.25-5.88-6.58-6.03

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$32.8m$32.8m$13.7m$19.4m$29.4m$23.9m$9.5m$14.2m$13.3m$18.0m
Cash and short-term investments$26.6m$28.9m$9.0m$11.2m$24.8m$20.0m$6.5m$10.3m$10.9m$15.6m
Total liabilities$2.3m$2.6m$3.9m$3.2m$4.2m$2.2m$2.0m$2.4m$1.9m$1.1m
Debt$137,749$110,681$113,236$149,788$83,649$46,740$24,027———
Shareholders' equity$30.4m$30.2m$9.8m$16.2m$25.3m$21.7m$7.5m$11.8m$11.4m$16.9m
Shares outstanding18m17m9m4m4m4m2m1m1m1m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$15.7m−$8.2m−$9.0m−$14.3m−$8.8m−$12.3m−$6.7m−$9.9m−$4.4m−$4.2m
Capital spending−$15.7m−$2−$4,074−$5,205−$63,470−$7,456−$11,921−$4,999−$44,431−$19,877
Free cash flow−$31.4m−$8.2m−$9.0m−$14.3m−$8.8m−$12.3m−$6.7m−$9.9m−$4.5m−$4.2m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Revenue——$2.7m$1.1m$571,688$1.5m$754,180$1.4m
Operating income−$11.1m−$9.1m−$5.0m−$5.3m−$2.7m−$9.2m−$4.6m−$3.2m
Net income−$10.0m−$6.7m−$3.5m−$5.1m−$2.6m−$9.0m−$4.5m−$4.6m
Diluted earnings per share-0.55-0.40-0.21-0.58-0.29-1.01-0.51-1.11
Cash from operations−$9.0m−$7.0m−$1.0m−$5.0m−$2.0m−$5.0m—−$3.0m
Capital spending−$9.0m−$7.0m——————
Free cash flow−$18.0m−$14.0m——————
Total assets$32.8m$40.5m$32.8m$7.5m$7.5m$13.7m$13.7m$15.8m
Cash and short-term investments$26.6m$35.0m$28.9m$3.2m$3.2m$9.0m$9.0m$8.8m
Debt$39,285$23,463$47,640$44,650$44,650$76,274$76,274$127,509
Shareholders' equity$30.4m$38.6m$30.2m$5.5m$5.5m$9.8m$9.8m$12.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income23.8%12.9%12.5%
Net income18.4%8.4%11.5%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-2.4-6.0-2.1-1.1-1.5-2.6-4.1-1.3-1.9-5.2
Price to sales—13.510.23.73.89.3100.9146.180.0294.5

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return40%-20%-13%-63%-43%55%-21%-63%63%-54%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 9 Jan 2023
  • 6-to-1 reverse split · 24 Mar 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.